LABORATOIRE BIODIM

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

  • No Technology to Display

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

  • No Recent Publications to Display

Recent Patents

  • No Recent Patents to Display

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
8197821 Human immunodeficiency virus integrase—Transportin—SR protein—protein interactionsExpiredFeb 25, 08Jun 12, 12[A61K, C07K]
2012/0022,054 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTSAbandonedDec 10, 09Jan 26, 12[A61K, C07D, A61P]
2011/0236,886 PATHOGENICITY DETERMINANTS WHICH CAN BE USED AS TARGETS FOR DEVELOPING MEANS FOR PREVENTING AND CONTROLLING BACTERIAL INFECTIONS AND/OR SYSTEMIC DISSEMINATIONAbandonedMar 23, 10Sep 29, 11[C07H, C12Q, C12N, C07K]
2010/0316,647 COMPOSITIONS OF POLYPEPTIDES SPECIFIC TO PATHOGENIC STRAINS AND THEIR USE AS VACCINES AND IN IMMUNOTHERAPYAbandonedJul 21, 10Dec 16, 10[A61K, C12N, A61P, C07K]
2010/0260,789 PRODUCTS SPECIFIC TO PATHOGENIC STRAINS AND THEIR USE AS VACCINES AND IN IMMUNOTHERAPYAbandonedJun 10, 09Oct 14, 10[A61K, C12Q, A61P, C07K]
2010/0261,618 Identification of genes implicated in the virulence of streptococcus agalactiaeAbandonedJun 19, 07Oct 14, 10[C07H, C12Q, C12N, C40B, C07K]
2009/0081,224 Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotheraphyAbandonedMar 29, 05Mar 26, 09[A61K, C12N]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.